Arch Biopartners Inc., of Toronto, grossed C$130,000 (US$97,600) from the exercising of 260,000 warrants to buy common shares at C$0.50 per share. There are 40,000 warrants of this issuance, which expire by September 2019, that are still outstanding. Read More
Disarm Therapeutics Inc., of Cambridge, Mass., published two articles in Science about the structure and function of SARM1, a protein that helps regulate cellular degeneration. Both articles involve the centrality of the NAD+-cleavage pathway in mediating cellular degeneration across multiple species. Disarm is working on treatments for multiple sclerosis, amyotrophic lateral sclerosis, and peripheral neuropathies. Read More
Information technology has been promising for decades, largely since the advent of electronic medical records, to improve and streamline health care as it has multiplied productivity in countless other industries. In addition to the long-standing problems with EMRs, more recently there have been early disappointments with the latest iteration of IT focused on artificial intelligence and machine learning, as big players like IBM Watson and Google have tended to over-promise and under-deliver with algorithms that are poorly matched to the data or the patient need. Read More
The U.S. Supreme Court's decision in Alice earlier this decade has closed the door on many drug and device patents involving artificial intelligence, as such claims are likely to be dismissed as abstract ideas, which means they can't get through what's become the patent eligibility rabbit hole of Section 101 of the Patent Act. Read More
Winter is coming to the artificial intelligence industry. While it's springtime for investment and technological advancement, gray skies hover over the talent pool. Read More
The hype surrounding artificial intelligence (AI) can make it sound like the technology has all the answers. But from a scientific perspective, one of the technology's biggest strengths is that it can ask better questions. Read More
LONDON – The first detailed map of gene expression in the malaria parasite Plasmodium shows exactly which genes are active at each stage of the complex life cycle of the single cell organism in the mosquito vector and the human host. Read More
Efforts to lower drug prices have led to a steady increase in FDA approvals of abbreviated new drug applications (ANDAs), including first-time generics. With 73 approvals currently, and a projected 109 by the end of the year, the number of first-time generic approvals has risen 49% since 2016. When looking at approvals of all abbreviated new drug applications, including tentative approvals, the FDA has given its seal to nearly 28% more than it did three years ago. Read More
TRK inhibitors, like essentially all targeted therapies, are vulnerable to resistance mutations, and several resistance mutations to Vitrakvi and the recently approved Rozlytrek have been described. The most common form of resistance to targeted therapies, and the only mechanisms that have been described for TRK inhibitors to date, are due to mutations in the target itself. Now, researchers at Memorial Sloan-Kettering Cancer Center have described resistance to TRK inhibitors that occurred due to activation of the MAP kinase (MAPK) pathway. Read More
